GLP-1 and Cardiovascular Health: What the Research Says

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

GLP-1 therapies improve cardiovascular health by reducing heart disease risk, lowering blood pressure, and enhancing blood vessel function. Research supports their protective benefits. Consult a healthcare provider for personalized advice.

# GLP-1 and Cardiovascular Health: What the Research Says

Glucagon-like peptide-1 (GLP-1) has gained significant attention in recent years, not only for its role in glucose metabolism but also for its potential benefits in cardiovascular health. Originally studied in the context of type 2 diabetes management, GLP-1 receptor agonists have shown promising effects on heart disease outcomes, making them a topic of considerable interest among researchers, clinicians, and patients alike.

This article explores the relationship between GLP-1 and cardiovascular health, reviews current evidence from clinical studies, and discusses practical considerations related to GLP-1 therapies.

---

What is GLP-1?

GLP-1 is an incretin hormone produced in the gut in response to food intake. Its primary functions include:

  • Stimulating insulin secretion from the pancreas in a glucose-dependent manner.
  • Suppressing glucagon release.
  • Delaying gastric emptying.
  • Promoting satiety and reducing appetite.

    • Because of these actions, GLP-1 plays a crucial role in blood sugar regulation and body weight management.

    ---

    GLP-1 Receptor Agonists: Beyond Blood Sugar Control

    GLP-1 receptor agonists (GLP-1 RAs) are a class of medications that mimic the effects of natural GLP-1 but have longer half-lives, allowing for therapeutic use. Common GLP-1 RAs include:

  • Exenatide (Byetta, Bydureon)
  • Liraglutide (Victoza, Saxenda)
  • Dulaglutide (Trulicity)
  • Semaglutide (Ozempic, Rybelsus)
  • Albiglutide (Tanzeum) – discontinued in some markets

    • Initially approved for type 2 diabetes, these drugs have demonstrated cardiovascular benefits in large clinical trials.

    ---

    Cardiovascular Benefits of GLP-1: What Does the Research Show?

    Reduction in Major Adverse Cardiovascular Events (MACE)

    Several landmark trials have evaluated the cardiovascular outcomes of GLP-1 RAs in patients with type 2 diabetes, many of whom are at high risk for cardiovascular disease (CVD).

  • LEADER Trial (Liraglutide):

    • This study showed a 13% relative risk reduction in major adverse cardiovascular events (MACE), which include cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, compared to placebo over 3.8 years. Liraglutide also reduced cardiovascular mortality by 22%.

    Reference: Marso SP et al., NEJM 2016

  • SUSTAIN-6 Trial (Semaglutide):

    • Semaglutide reduced the risk of MACE by 26% compared to placebo over 2 years. It also showed significant reductions in nonfatal stroke.

    Reference: Marso SP et al., NEJM 2016

  • REWIND Trial (Dulaglutide):

    • This trial demonstrated a 12% reduction in MACE in a broader population, including patients with and without established cardiovascular disease, over a median of 5.4 years.

    Reference: Gerstein HC et al., NEJM 2019

    Impact on Heart Failure and Blood Pressure

    GLP-1 RAs have modest effects on reducing systolic blood pressure (typically 2-4 mm Hg) and promoting weight loss, both of which are beneficial for cardiovascular health. However, their effect on heart failure outcomes is less clear, with some studies showing no significant benefit.

    Mechanisms Behind Cardiovascular Protection

    Although the exact mechanisms remain under investigation, several pathways have been proposed:

  • Improved endothelial function: GLP-1 may enhance blood vessel health.
  • Anti-inflammatory effects: Reduction of systemic inflammation.
  • Weight loss: Reducing obesity-related cardiovascular risk.
  • Blood pressure reduction: Lowering vascular strain.
  • Direct cardiac effects: Potential improvement in heart muscle metabolism and function.

    • ---

    Practical Protocol Information: GLP-1 RA Use in Cardiovascular Risk Management

    Indications

    GLP-1 RAs are primarily indicated for type 2 diabetes but are increasingly used for cardiovascular risk reduction in patients with established atherosclerotic cardiovascular disease (ASCVD).

    Typical Dosing Examples

    *Note